A citation-based method for searching scientific literature

Thomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst, Sten Madsbad. Expert Opin Biol Ther 2016
Times Cited: 9







List of co-cited articles
39 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
44

Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
David Russell-Jones, Rehman Khan. Diabetes Obes Metab 2007
303
44

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
72
33

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
33

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
33

Temporal patterns in overweight and obesity in Type 1 diabetes.
B Conway, R G Miller, T Costacou, L Fried, S Kelsey, R W Evans, T J Orchard. Diabet Med 2010
179
33

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
33

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
33

Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Marie-Christine Dubé, Martin D'Amours, S John Weisnagel. Diabetes Obes Metab 2018
13
33


Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
55
22

Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes.
Giuliana Valerio, Dario Iafusco, Stefano Zucchini, Claudio Maffeis. Diabetes Res Clin Pract 2012
31
22

Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
Mojca Jensterle, Tomaz Kocjan, Nika Aleksandra Kravos, Marija Pfeifer, Andrej Janez. Endocr Res 2015
40
22


Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.
Kathrin Herrmann, Steven C Brunell, Yan Li, Ming Zhou, David G Maggs. Adv Ther 2016
12
22


Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
143
22

Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study.
Paweł Burchardt, Agnieszka Zawada, Piotr Tabaczewski, Dariusz Naskręt, Jolanta Kaczmarek, Justyna Marcinkaniec, Bogna Wierusz-Wysocka, Henryk Wysocki. Pol Arch Med Wewn 2013
17
22

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
134
22

Bariatric Surgery in Obese Patients with Type 1 Diabetes: Effects on Weight Loss and Metabolic Control.
Pauline Faucher, Christine Poitou, Claire Carette, Sophie Tezenas du Montcel, Charles Barsamian, Eliabelle Touati, Jean-Luc Bouillot, Adriana Torcivia, Sébastien Czernichow, Jean-Michel Oppert,[...]. Obes Surg 2016
15
22



Intensive diabetes therapy and body weight: focus on insulin detemir.
Michael A Bush. Endocrinol Metab Clin North Am 2007
10
22


Exercise management in type 1 diabetes: a consensus statement.
Michael C Riddell, Ian W Gallen, Carmel E Smart, Craig E Taplin, Peter Adolfsson, Alistair N Lumb, Aaron Kowalski, Remi Rabasa-Lhoret, Rory J McCrimmon, Carin Hume,[...]. Lancet Diabetes Endocrinol 2017
297
22

Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.
Rebecca Schechter, Sirimon Reutrakul. Curr Diab Rep 2015
8
25

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
231
22

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.
Marie L Misso, Kristine J Egberts, Matthew Page, Denise O'Connor, Jonathan Shaw. Cochrane Database Syst Rev 2010
276
22

Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis.
Cong Liu, Dan Wu, Xuan Zheng, Ping Li, Ling Li. Diabetes Technol Ther 2015
30
22

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
46
22

Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
Frederik Staels, Carolien Moyson, Chantal Mathieu. Diabetes Obes Metab 2017
15
22


Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
102
22

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50
22

GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
Isabella Crisci, Michele Aragona, Konstantina Savvina Politi, Giuseppe Daniele, Stefano Del Prato. Acta Diabetol 2015
10
22

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
Christian S Frandsen, Thomas F Dejgaard, Henrik U Andersen, Jens J Holst, Bolette Hartmann, Birger Thorsteinsson, Sten Madsbad. Diabetes Obes Metab 2017
14
22


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
22

Regulation of energy balance and body weight by the brain: a distributed system prone to disruption.
Lucy F Faulconbridge, Matthew R Hayes. Psychiatr Clin North Am 2011
16
11

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies.
Steven P Marso, Jason B Lindsey, Joshua M Stolker, John A House, Gabriela Martinez Ravn, Kevin F Kennedy, Troels M Jensen, John B Buse. Diab Vasc Dis Res 2011
89
11

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
160
11

Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study.
Magnus T Jensen, Jacob L Marott, Kristine H Allin, Børge G Nordestgaard, Gorm B Jensen. Eur J Prev Cardiol 2012
86
11

Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.
Hideaki Jinnouchi, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Noboru Kurinami, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Kunihiko Matsui, Tomio Jinnouchi. J Diabetes Res 2015
26
11

Impact of overweight on chronic microvascular complications in type 1 diabetic patients.
Christophe E M De Block, Ivo H De Leeuw, Luc F Van Gaal. Diabetes Care 2005
76
11

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
292
11

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
11

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
11

Glycemic control and excess mortality in type 1 diabetes.
Marcus Lind, Ann-Marie Svensson, Mikhail Kosiborod, Soffia Gudbjörnsdottir, Aldina Pivodic, Hans Wedel, Sofia Dahlqvist, Mark Clements, Annika Rosengren. N Engl J Med 2014
427
11

Beneficial health effects of modest weight loss.
D J Goldstein. Int J Obes Relat Metab Disord 1992
925
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.